Ultime notizie per Celanese (NYSE:CE) Azioni

Celanese

Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.

Celanese Corp

CE Energy Acquisition Corp.

CEA Industries Inc

Creations Inc

CEA Space Partners I Corp.

CENTRAL AUTOMOTIVE PRODS by Central Automotive Products Ltd.

Central Automotive Products Ltd

China Eastern Airlines Corp Ltd ADR

CHINA EVERBRIGHT BANK ORD by China Everbright Bank Co Ltd.

China Everbright Bank Co Ltd

CITYCHAMP WATCH & JEWELLE by Citychamp Watch & Jewellery Group Ltd.

Citychamp Watch & Jewellery Group Ltd

Cebu Air Inc

CANASIA ENERGY CORP by CANASIA ENERGY CORP.

CanAsia Energy Corp

Saltbae Capital Corp

Cecil Bancorp Inc

CECO Environmental Corp

Cedarlake Acquisition Corp

The Central and Eastern Europe Fund, Inc. (The) Common Stock

CENTRAL & EASTERN EUROPE FUND, INC.

Ceres Inc

CEEK VR

UpSnap Inc

Sprott Physical Gold and Silver Trust Units

Sprott Physical Gold and Silver Trust

Global X S&P Catholic Values Developed ex-U.S. ETF

CENTRAL FLA ST BK BELLEVW by Central Florida State Bank (Belleview FL)

COMML NATL FINCL CRP MICH by Commercial National Financial Corp (MI)

Commercial National Financial Corp (MI)

ETRACS Monthly Pay 1.5X Leveraged Closed-End Fund Index ETN

Saba Closed-End Funds ETF

Constellation Energy Corporation - Common Stock

Constellation Energy Corp

CHINA ED GROUP HLDGS LTD by CHINA ED GROUP HLDGS LTD.

China Education Group Holdings Ltd

CERRO GRANDE MINING CORP by Cerro Grande Mining Corp.

Cerro Grande Mining Corp

COSMO ENERGY HLDGS CO LTD by Cosmo Energy Hldgs Co Ltd

Cosmo Energy Holdings Co Ltd

Camber Energy Inc OM PAR $0.001 2022 NEW

COMPAL ELECTRONIC 144A GDR REP 5 ORD

COELACANTH ENERGY INC by COELACANTH ENERGY INC

Coelacanth Energy Inc

Camber Energy Inc

COMPAL USD DR

CONSOL Energy Inc

CONSOL ENERGY ORD

Cresco Ltd

Celsius - United States Dollar

Celcuity Inc

Bristol-Myers Squibb Company Celegne Contingent Value Rights

Celsius Holdings Inc

CELLCOM ISRAEL LTD ORD by Cellcom Israel, Ltd.

Cellcom Israel Ltd

Cellframe

Celo - United States Dollar

Celer Network - United States Dollar

Centamin PLC

CENTAMIN ORD

Celularity Inc

PREFERRED COMMERCE INC by Preferred Commerce Inc.

Preferred Commerce Inc

Celexpress Inc

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Technology Holdings Inc

ClearBridge MLP & Midstream Fund Inc Com (New)

ISHRS MSCI EM ASIA UCITS USD ETF

iShares J.P. Morgan EM Corporate Bond ETF

ISHRS MSCI EM CNSMR GRWTH USD ETF

CEN Biotech Inc

Caravan Energy Corp Ordinary Shares

CareNet Inc

Cenntro Inc

CENNZnet

Central Garden & Pet Company - Common Stock

Central Garden & Pet Co

Central Garden & Pet Company - Class A Common Stock Nonvoting

Century Aluminum Co

CENTURY ALUMINUM ORD

CEO America Inc

CeCors Inc

Cantor Equity Partners, Inc. - Class A ordinary shares

Cantor Equity Partners Inc

Cantor Equity Partners I, Inc

CEPS PLC

Central Puerto S.A. American Depositary Shares (each represents ten Common Shares)

Central Puerto SA

Crestwood Equity Partners LP Unit Ltd Partnership Int (New)

CERES INC OM NEW

Cere Network

CERES GLOBAL AG CORP ORD by Ceres Global Ag Corp.

Ceres Global Ag Corp

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Holdings Inc

CERo Therapeutics Holdings, Inc. - Warrants

Cerus Corp

Certara Inc

COLOMBIA ENERGY RESOUR by Colombia Energy Resources, Inc.

Colombia Energy Resources Inc

SPDR Series Trust SPDR Bloomberg Enhanced Roll Yield Commodity Strategy No K-1 ETF

CES ENERGY SOLUTIONS ORD by CES Energy Solutions Corp.

CES Energy Solutions Corp

Celanese will continue to take actions commensurate with the current demand environment. To this end, the Company intends to temporarily reduce the quarterly dividend by approximately 95 percent beginning in the first quarter of 2025. This action is a prudent and cost-effective path forward to support deleveraging. In addition, Celanese is taking the following actions to drive continued improvement to earnings and cash generation:
<ul>
<li>Reducing manufacturing costs through the end of 2024 by temporarily idling production facilities in every region and driving cash generation through an expected $200 million inventory release in the fourth quarter.</li>
<li>Implementing additional cost reduction programs expected to realize incremental savings greater than $75 million by the end of 2025. The focus of the programs will be on driving productivity in selling, general, and administrative (SG&amp;A) costs.</li>
<li>Continuing to focus on efficiently and stringently deploying capital, and targeting next year's capex spending to be below 2024 levels.</li>
<li>Closing on a 364-day delayed draw prepayable term loan for up to $1 billion. The Company expects to draw on the term loan in the first quarter of 2025 for use towards the $1.3 billion maturing debt.</li>
</ul>

News

Guidance

Celanese Reducing Manufacturing Costs Through The End Of 2024 By Temporarily Idling Production Facilities In Every Region And Driving Cash Generation Through An Expected $200M Inventory Release In Q4. Implementing Additional Cost Reduction Programs Expected To Realize Incremental Savings Greater Than $75M By The End Of 2025.

Outlook
"We expect demand conditions to worsen in the fourth quarter, as automotive and industrial segments react to recent dynamics by seasonally destocking at heavier than normal levels. While we expect this destocking to be temporary and contained to the quarter, we will significantly slow our production to match this demand level and to generate cash through inventory draw. Based on these factors, we anticipate fourth quarter adjusted earnings per share of approximately $1.25," said Lori Ryerkerk. "We hold ourselves to a high standard at Celanese, and are taking additional actions to strengthen our company. Our focus is on driving business improvement through earnings growth, cost reductions, free cash flow expansion, and deleveraging to position Celanese for long-term shareholder value creation."
Reconciliations of forecasted non-GAAP measures such as adjusted earnings per share, adjusted EBIT or free cash flow to the equivalent U.S. GAAP measures (diluted earnings per share, net earnings (loss) attributable to Celanese Corporation and net cash provided by (used in) operations, respectively), are not available without unreasonable efforts because a forecast of Certain Items, such as mark-to-market pension gains/losses, and other items is not practical. For more information, see "Non-GAAP Financial Measures" below.
The Company's prepared remarks related to the third quarter will be posted on its website at investors.celanese.com under Financial Information/Financial Document Library on November 4, 2024. Information about Non-US GAAP measures is included in a Non-US GAAP Financial Measures and Supplemental Information document posted on our investor relations website under Financial Information/Non-GAAP Financial Measures. See also "Non-GAAP Financial Measures" below.
Celanese Corporation is a global leader in chemistry, producing specialty material solutions used across most major industries and consumer applications. Our businesses use our chemistry, technology and commercial expertise to create value for our customers, employees and shareholders. We support sustainability by responsibly managing the materials we create and growing our portfolio of sustainable products to meet customer and societal demand. We strive to make a positive impact in our communities and to foster inclusivity across our teams. Celanese Corporation is a Fortune 500 company that employs approximately 12,400 employees worldwide with 2023 net sales of $10.9 billion.

Celanese Says "We Expect Demand Conditions To Worsen In Q4, As Automotive And Industrial Segments React To Recent Dynamics By Seasonally Destocking At Heavier Than Normal Levels. While We Expect This Destocking To Be Temporary And Contained To The Quarter, We Will Significantly Slow Our Production To Match This Demand Level And To Generate Cash Through Inventory Draw. Based On These Factors, We Anticipate Q4 Adj EPS Of ~$1.25"

WIIM

Celanese shares are trading lower after the company reported worse-than-expected Q3 financial results and announced it intends to temporarily reduce its quarterly dividend.

Dividends

Celanese Intends To Temporarily Reduce The Quarterly Dividend By ~95% Beginning In Q1 2025

Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) reported quarterly earnings of $2.44 per share which missed the analyst consensus estimate of $2.85 by 14.39 percent. This is a 2.4 percent decrease over earnings of $2.50 per share from the same period last year. The company reported quarterly sales of $2.65 billion which missed the analyst consensus estimate of $2.70 billion by 1.93 percent. This is a 2.75 percent decrease over sales of $2.72 billion the same period last year.

Earnings

Earnings Misses

Celanese Q3 Adj $2.44 Misses $2.85 Estimate, Sales $2.65B Miss $2.70B Estimate

With U.S. stock futures trading mixed this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) to report quarterly earnings at $2.64 per share on revenue of $5.71 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Constellation Energy shares fell 5.5% to $243.99 in after-hours trading.</li>
<li>Analysts expect Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) to post quarterly earnings at $2.31 per share on revenue of $6.27 billion. The company will release earnings before the markets open. Marriott shares gained 0.5% to $261.75 in after-hours trading.</li>
<li>Chewy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) will replace Stericycle Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRCL#NASDAQ">SRCL</a>) in the S&amp;P MidCap 400 before the opening bell on Wednesday, Nov. 6. Waste Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) is acquiring Stericycle in a transaction expected to be completed soon. Chewy shares surged 5.1% to $28.51 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>After the markets close, Wynn Resorts, Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) is projected to report quarterly earnings at $1.01 per share on revenue of $1.73 billion. Wynn Resorts shares gained 0.2% to $95.87 in the after-hours trading session.</li>
<li>Analysts expect Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) to report quarterly earnings at $2.85 per share on revenue of $2.7 billion after the closing bell. Celanese shares gained 1.5% to $126.70 in after-hours trading.</li>
</ul>
Check This Out:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>
Photo courtesy: Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

CHWY

SRCL

WYNN

Marriott, Constellation Energy And 3 Stocks To Watch Heading Into Monday

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $148.75, a high estimate of $178.00, and a low estimate of $128.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 10.09%. 
<img src="https://www.benzinga.com/files/images/story/2024/1730217656_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Celanese among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin McCarthy</td>
<td>Vertical Research</td>
<td>Announces</td>
<td>Sell</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$163.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$135.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$128.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$167.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$138.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$151.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$178.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ghansham Panjabi</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$156.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celanese. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celanese compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Celanese's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Celanese's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Celanese analyst ratings.</a>
<h2>Discovering Celanese: A Closer Look</h2>
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.
<h3>Understanding the Numbers: Celanese's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Celanese's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -5.15%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 5.85%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.18%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Celanese's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.6%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Celanese's debt-to-equity ratio surpasses industry norms, standing at 1.87. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Expectations For Celanese's Future

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Vertical Research analyst Kevin McCarthy downgraded the rating for Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Hold to Sell and announced a $130 price target. Celanese shares closed at $129.97 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Simon Leopold downgraded Harmonic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) from Strong Buy to Outperform and slashed the price target from $17 to $14. Harmonic shares closed at $14.82 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Adrian Huerta downgraded CEMEX, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CX#NYSE">CX</a>) from Overweight to Neutral and lowered the price target from $7 to $6. Cemex shares closed at $5.46 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen analyst Oliver Chen downgraded the rating for Tapestry, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) from Buy to Hold and maintained the price target of $52. Tapestry shares closed at $50.47 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B. Riley Securities analyst Mike Crawford downgraded Redwire Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) from Buy to Neutral and raised the price target from $8 to $9.5. Redwire shares closed at $9.19 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="523" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29095706/image-302-1024x523.png" alt="" class="wp-image-619542" style="width:640px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29095706/image-302-1024x523.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29095706/image-302-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29095706/image-302-768x392.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29095706/image-302.png 1312w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More:<a href="https://www.benzinga.com/news/24/10/41598310/jim-cramer-avoid-this-consumer-cyclical-stock-buy-lam-research"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41598310/jim-cramer-avoid-this-consumer-cyclical-stock-buy-lam-research">Jim Cramer: &#8216;Avoid&#8217; This Consumer Cyclical Stock, Buy Lam Research</a></li>
</ul>

Downgrades

HLIT

This Celanese Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Vertical Research analyst Kevin McCarthy downgrades Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Hold to Sell and announces $130 price target.

Price Target

Vertical Research Downgrades Celanese to Sell, Announces $130 Price Target

RBC Capital analyst Arun Viswanathan maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Outperform and lowers the price target from $167 to $163.

RBC Capital Maintains Outperform on Celanese, Lowers Price Target to $163

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d11d3db85e93000188d7b6/alexia-howard">Bernstein analyst Alexia Howard</a> downgraded the rating for The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) from Outperform to Market Perform and lowered the price target from $230 to $205. Hershey shares gained 0.5% to close at $191.84 on Friday. <a href="https://www.benzinga.com/quote/HSY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Aleksey Yefremov downgraded the rating for Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Overweight to Sector Weight. Celanese shares gained 2.1% to close at $136.67 on Friday. <a href="https://www.benzinga.com/quote/CE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586e4053351b9b00018bee9e/kannan-venkateshwar">Barclays analyst Kannan Venkateshwar </a>downgraded the rating for Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from Equal-Weight to Underweight and maintained the price target of $550. Netflix shares gained 1.8% to close at $719.70 on Friday. <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Bryan Spillane downgraded Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) from Buy to Neutral and slashed the price target from $300 to $255. Constellation shares gained 1.2% to close at $246.67 on Friday. <a href="https://www.benzinga.com/quote/STZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group analyst Ross Muken downgraded the rating for Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Outperform to In-Line and cut the price target from $225 to $190. Charles River shares gained 0.6% to close at $190.74 on Friday. <a href="https://www.benzinga.com/quote/CRL/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying NFLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="512" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07080259/image-34-1024x512.png" alt="" class="wp-image-583229" style="width:568px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07080259/image-34-1024x512.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07080259/image-34-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07080259/image-34-768x384.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07080259/image-34.png 1333w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41196046/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yiel">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>

NFLX

This Netflix Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

11 analysts have expressed a variety of opinions on Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Celanese and provided 12-month price targets. The average target is $152.0, accompanied by a high estimate of $180.00 and a low estimate of $128.00. This current average has decreased by 9.28% from the previous average price target of $167.55. 
<img src="https://www.benzinga.com/files/images/story/2024/1728302494_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Celanese is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$135.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$128.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$167.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$138.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$151.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$178.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ghansham Panjabi</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celanese. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celanese compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Celanese's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Celanese's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Celanese analyst ratings.</a>
<h2>Delving into Celanese's Background</h2>
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.
<h3>Financial Insights: Celanese</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Decline in Revenue: Over the 3 months period, Celanese faced challenges, resulting in a decline of approximately -5.15% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Celanese's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 5.85%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Celanese's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.18%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.6%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Celanese's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.87, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Celanese: 11 Analysts Share Their Views

Keybanc analyst Aleksey Yefremov downgrades Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Overweight to Sector Weight.

Keybanc Downgrades Celanese to Sector Weight

U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Thursday.
Shares of Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) rose sharply in today's session after the company reported better-than-expected fourth-quarter financial results and approved a $1 billion share buyback.
Jabil reported fourth-quarter revenue of $6.96 billion, down by 17.7% year-on-year, beating the analyst consensus estimate of $6.59 billion. The print manufacturing company's adjusted EPS of $2.30 beat the analyst consensus estimate of $2.22.
Jabil shares jumped 11.2% to $126.18 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>SBC Medical Group Holdings Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBC#NYSE">SBC</a>) jumped 25.4% to $10.01.</li>
<li>Gaotu Techedu Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOTU#NYSE">GOTU</a>) shares jumped 25.4% to $3.65.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) gained 24.1% to $4.9650.</li>
<li>TAL Education Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) gained 21.7% to $10.13.</li>
<li>Ispire Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>) surged 18.6% to $6.91 following FY24 financial results.</li>
<li>Studio City International Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSC#NYSE">MSC</a>) gained 17.8% to $7.43.</li>
<li>KE Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) surged 17.4% to $19.22. Shares of Chinese stocks traded higher following a report suggesting China will issue up to $284 billion of sovereign debt as part of a stimulus.</li>
<li>H World Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) gained 16.7% to $36.60. Shares of Chinese stocks traded higher following a report suggesting China will issue up to $284 billion of sovereign debt as part of a stimulus.</li>
<li>New Oriental Education &amp; Technology Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) gained 14.4% to $71.19.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) gained 14.2% to $109.37 following strong quarterly results.</li>
<li>Yum China Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) jumped 14.2% to $43.60.</li>
<li>The Estée Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) gained 10% to $100.78.</li>
<li>Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) climbed 9.9% to $31.19 after the company announced it plans a $2.5 billion share repurchase program and issued its third-quarter RASM guidance. Also, the company announced it reduced headcount through controlled hiring and attrition and has contracts with all labor groups.</li>
<li>Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) gained 9.7% to $104.73 following a report suggesting China will issue up to $284 billion of sovereign debt as part of a stimulus.</li>
<li>Trip.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) rose 9.1% to $55.74.</li>
<li>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) gained 6.6% to $138.71.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41045737/top-3-materials-stocks-youll-regret-missing-this-quarter">Top 3 Materials Stocks You&#8217;ll Regret Missing This Quarter</a></li>
</ul>

Movers

ADPT

BABA

BEKE

New Oriental Education & Technology Group

GSX Techedu Inc. American Depositary Shares

GOTU

HTHT

ISPR

TCOM

YUMC

Jabil Posts Upbeat Earnings, Joins Micron Technology, Southwest Airlines And Other Big Stocks Moving Higher On Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Piper Sandler cut the price target for C3.ai, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) from $29 to $24. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. C3.ai shares fell 1.9% to close at $23.01 on Wednesday. <a href="https://www.benzinga.com/quote/AI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. raised the price target for Collegium Pharmaceutical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) from $47 to $50. HC Wainwright &amp; Co. analyst Oren Livnat maintained a Buy rating. Praxis Collegium Pharmaceutical shares gained 2.2% to close at $38.24 on Wednesday. <a href="https://www.benzinga.com/quote/COLL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham cut ChargePoint Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) price target from $3 to $2. Needham analyst Chris Pierce maintained a Buy rating. ChargePoint shares fell 0.6% to close at $1.69 on Wednesday. <a href="https://www.benzinga.com/quote/CHPT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) price target from $530 to $564. Morgan Stanley analyst Toni Kaplan maintained an Overweight rating. S&amp;P Global shares gained 0.5% to close at $513.31 on Wednesday. <a href="https://www.benzinga.com/quote/SPGI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital cut the price target for Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) from $130 to $68. BMO Capital analyst Kelly Bania downgraded the stock from Outperform to Market Perform. Dollar Tree shares fell 22.2% to close at $63.56 on Wednesday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs raised Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) price target from $119 to $121. Goldman Sachs analyst James Quigley downgraded the stock from Buy to Neutral. Novartis shares rose 0.7% to close at $119.38 on Wednesday. <a href="https://www.benzinga.com/quote/NVS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut Core &amp; Main, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNM#NYSE">CNM</a>) price target from $62 to $53. Baird analyst David Manthey maintained an Outperform rating. Core &amp; Main shares fell 15.8% to close at $39.40 on Wednesday. <a href="https://www.benzinga.com/quote/CNM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Susquehanna slashed the price target for EVERTEC, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTC#NYSE">EVTC</a>) from $38 to $28. Susquehanna analyst James Friedman downgraded the stock from Neutral to Negative. EVERTEC shares rose 0.3% to close at $33.73 on Wednesday. <a href="https://www.benzinga.com/quote/EVTC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) price target from $180 to $150. Piper Sandler analyst Charles Neivert downgraded the stock from Overweight to Neutral. Celanese shares fell 0.8% to close at $124.31 on Wednesday.<a href="https://www.benzinga.com/quote/CE/analyst-ratings"> See how other analysts view this stock.</a></li>
<li>Morgan Stanley lowered StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) price target from $16.5 to $7. Morgan Stanley analyst Jorge Kuri downgraded the stock from Equal-Weight to Underweight. StoneCo shares fell 3.8% to close at $12.61 on Wednesday.<a href="https://www.benzinga.com/quote/STNE/analyst-ratings"> See how other analysts view this stock.</a></li>
</ul>
Considering buying SPGI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="522" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05081724/image-36-1024x522.png" alt="" class="wp-image-531810" style="width:536px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05081724/image-36-1024x522.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05081724/image-36-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05081724/image-36-768x391.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/05081724/image-36.png 1321w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

CHPT

COLL

DLTR

EVTC

SPGI

STNE

S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday

In the preceding three months, 17 analysts have released ratings for Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Celanese, presenting an average target of $155.65, a high estimate of $184.00, and a low estimate of $128.00. Experiencing a 8.06% decline, the current average is now lower than the previous average price target of $169.29. 
<img src="https://www.benzinga.com/files/images/story/2024/1725537687_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Celanese among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$135.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$128.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$167.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$138.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$151.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$178.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ghansham Panjabi</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$184.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$148.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$158.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$160.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$144.00</td>
<td>$147.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celanese. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celanese compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Celanese's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Celanese analyst ratings.</a>
<h2>About Celanese</h2>
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.
<h3>Key Indicators: Celanese's Financial Health</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Negative Revenue Trend: Examining Celanese's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -5.15% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Celanese's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 5.85%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.18%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Celanese's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.6%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.87, caution is advised due to increased financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 17 Ratings For Celanese

Piper Sandler analyst Charles Neivert downgrades Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Overweight to Neutral and lowers the price target from $180 to $150.

Piper Sandler Downgrades Celanese to Neutral, Lowers Price Target to $150

Deutsche Bank analyst David Begleiter maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Hold and lowers the price target from $160 to $135.

Deutsche Bank Maintains Hold on Celanese, Lowers Price Target to $135

B of A Securities analyst Steve Byrne maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Underperform and lowers the price target from $137 to $128.

B of A Securities Maintains Underperform on Celanese, Lowers Price Target to $128

RBC Capital analyst Arun Viswanathan maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Outperform and lowers the price target from $168 to $167.

RBC Capital Maintains Outperform on Celanese, Lowers Price Target to $167

Here are the major earnings after the close today

Reports Q3 revenue $2.6B, consensus $2.7B. "In the third quarter, we faced a severely constrained demand environment that, in some cases like auto,...

Celanese reports Q3 adjusted EPS $2.44, consensus $2.85

"We expect demand conditions to worsen in the fourth quarter, as automotive and industrial segments react to recent dynamics by seasonally destocki...

Celanese sees demand conditions worsening in Q4

Celanese Non-GAAP EPS of $2.44 misses by $0.40, revenue of $2.65B misses by $40M

Celanese ( ($CE) ) has provided an announcement. On November 5, 2024, Celanese Corporation's CEO, Lori J. Ryerkerk, will present the company's thir...

Celanese to Unveil Q3 Financial Results in Webcast

Celanese plunges after Q3 earnings disappoint; dividend cut 95%

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – QuinStreet&nbsp;(QNST)&nbsp;u...

Closing Bell Movers: Palantir jumps 13% after results

In a report released yesterday, Vincent Andrews from Morgan Stanley maintained a Hold rating on Celanese (CE – Research Report), with a price targe...

Celanese Hold Rating Due to Weak Performance and Market Challenges

Analysts have been eager to weigh in on the Materials sector with new ratings on LyondellBasell (LYB – Research Report) and Celanese (CE – Research...

Analysts' Opinions Are Mixed on These Materials Stocks: LyondellBasell (LYB) and Celanese (CE)

Celanese (CE – Research Report), the Basic Materials sector company, was revisited by a Wall Street analyst yesterday. Analyst John Roberts CFA fro...

Comments

Celanese

Notizie

Ultime notizie per Celanese (NYSE:CE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO